{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:38:12Z","timestamp":1783593492807,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-024-20761-w","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T09:07:02Z","timestamp":1733216822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The progress of mother-to-child transmission of Human Immunodeficiency Virus (HIV) after Dolutegravir (DTG) optimization program: evidence from a multicenter cohort study in Ethiopia"],"prefix":"10.1186","volume":"24","author":[{"given":"Abel","family":"Gedefaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birkneh Tilahun","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sintayehu","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biruk","family":"Kebede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj","family":"Hussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejene","family":"Hailu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifru","family":"Berhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyasu","family":"Makonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Vella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"issue":"4","key":"20761_CR1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.clp.2010.08.004","volume":"37","author":"AP Kourtis","year":"2010","unstructured":"Kourtis AP, Bulterys M. Mother-to-child transmission of HIV: pathogenesis, mechanisms and pathways. Clin Perinatol. 2010;37(4):721\u201337.","journal-title":"Clin Perinatol"},{"issue":"11","key":"20761_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(06)70629-6","volume":"6","author":"AP Kourtis","year":"2006","unstructured":"Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis. 2006;6(11):726\u201332.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"20761_CR3","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.283.9.1175","volume":"283","author":"KM De Cock","year":"2000","unstructured":"De Cock KM, Fowler MG, Mercier E, De Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283(9):1175\u201382.","journal-title":"JAMA"},{"key":"20761_CR4","unstructured":"WHO.  PMTCT strategic vision 2010\u20132015: preventing mother-to-child transmission of HIV to reach the UNGASS and Millennium Development Goals: moving towards the elimination of paediatric HIV, 2009. 2010."},{"key":"20761_CR5","unstructured":"UNAIDS. Miles to go: closing gaps, breaking barriers, righting injustices. 2018."},{"key":"20761_CR6","unstructured":"UNAIDS\/UNICEF. HIV\/AIDS data. Elimination of HIV transmission.: UNAIDS\/UNICEF 2023 [updated Last update: July 2023. ; cited 2023 September 30 ]. https:\/\/data.unicef.org\/wp-content\/uploads\/2019\/07\/HIV_Epidemiology_Children_Adolescents_2023.xlsx"},{"key":"20761_CR7","unstructured":"Ethiopia MOH . Guidelines for Prevention of Mother-to-child transmission of HIV in Ethiopia. In: Federal HIV\/AIDS Prevention and Control Office, editor. Addis Ababa; 2007."},{"key":"20761_CR8","unstructured":"Ethiopia MOH. Guidelines for Prevention of Mother-to-child transmission of HIV in Ethiopia, Addis Ababa. Ethiopia: Addis Ababa Federal Ministry of Health; 2001."},{"key":"20761_CR9","volume-title":"Guidelines for Prevention of Mother-to-child transmission of HIV in Ethiopia","author":"HIVAIDS Federal","year":"2011","unstructured":"Federal HIV AIDS, Prevention and Control Office Federal Ministry of Health. Guidelines for Prevention of Mother-to-child transmission of HIV in Ethiopia. Addis Ababa: Federal Ministry of Health; 2011."},{"key":"20761_CR10","volume-title":"National comprehensive and integrated prevention of mother-to-child transmission of HIV guideline","author":"Federal Democratic Republic of Ethiopia, Ministry of Health","year":"2017","unstructured":"Federal Democratic Republic of Ethiopia, Ministry of Health. National comprehensive and integrated prevention of mother-to-child transmission of HIV guideline. Addis Ababa: Federal Minstry of Health October; 2017."},{"key":"20761_CR11","unstructured":"National Guideline for Prevention of Mother-to-. Child transmission of HIV, Syphilis and Hepatitis B Virus. Addis Ababa Federal Ministry of Health, Ethiopia November; 2021."},{"key":"20761_CR12","unstructured":"Team IT. Guidance on global scale-up of the prevention of mother to child transmission of HIV: towards universal access for women, infants and young children and eliminating HIV and AIDS among children. 2007."},{"key":"20761_CR13","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization; 2016."},{"key":"20761_CR14","unstructured":"UNAIDS\/UNICEF. HIV\/AIDS data. Elimination of HIV transmission Last update: July 2023. https:\/\/data.unicef.org\/wp-content\/uploads\/2019\/07\/HIV_Epidemiology_Children_Adolescents_2023.xlsx"},{"key":"20761_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2016.07.006","volume":"239","author":"BG Brenner","year":"2017","unstructured":"Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res. 2017;239:1\u20139.","journal-title":"Virus Res"},{"key":"20761_CR16","unstructured":"WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization; 2021."},{"issue":"9","key":"20761_CR17","doi-asserted-by":"publisher","first-page":"e1002895","DOI":"10.1371\/journal.pmed.1002895","volume":"16","author":"C Waitt","year":"2019","unstructured":"Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study). PLoS Med. 2019;16(9):e1002895.","journal-title":"PLoS Med"},{"issue":"10281","key":"20761_CR18","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","volume":"397","author":"S Lockman","year":"2021","unstructured":"Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, et al. Efficacy and safety of dolutegravir-and tenofovir alafenamide fumarate-containing HIV antiretroviral treatment regimens started in pregnancy: a randomised controlled trial. Lancet (London England). 2021;397(10281):1276.","journal-title":"Lancet (London England)"},{"issue":"5","key":"20761_CR19","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(20)30050-3","volume":"7","author":"K Kintu","year":"2020","unstructured":"Kintu K, Malaba TR, Nakibuka J, Papamichael C, Colbers A, Byrne K, et al. Dolutegravir versus Efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. Lancet HIV. 2020;7(5):e332\u20139.","journal-title":"Lancet HIV"},{"issue":"8","key":"20761_CR20","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S2352-3018(22)00173-4","volume":"9","author":"TR Malaba","year":"2022","unstructured":"Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, et al. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. Lancet HIV. 2022;9(8):e534\u201343.","journal-title":"Lancet HIV"},{"key":"20761_CR21","doi-asserted-by":"crossref","unstructured":"Davey S, Ajibola G, Maswabi K, Sakoi M, Bennett K, Hughes MD et al. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana. Journal of acquired immune deficiency syndromes (1999). 2020;84(3):235\u2009\u2013\u200941.","DOI":"10.1097\/QAI.0000000000002338"},{"issue":"6","key":"20761_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/tmi.12881","volume":"22","author":"M Girma","year":"2017","unstructured":"Girma M, Wendaferash R, Shibru H, Berhane Y, Hoelscher M, Kroidl A. Uptake and performance of prevention of mother-to\u2010child transmission and early infant diagnosis in pregnant HIV\u2010infected women and their exposed infants at seven health centres in Addis Ababa, Ethiopia. Tropical Med Int Health. 2017;22(6):765\u201375.","journal-title":"Tropical Med Int Health"},{"key":"20761_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-018-3189-3","volume":"18","author":"A Endalamaw","year":"2018","unstructured":"Endalamaw A, Demsie A, Eshetie S, Habtewold TD. A systematic review and meta-analysis of vertical transmission route of HIV in Ethiopia. BMC Infect Dis. 2018;18:1\u201311.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"20761_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12887-023-04074-2","volume":"23","author":"G Gutema","year":"2023","unstructured":"Gutema G, Tola HH, Fikadu D, Leta D, Bejiga B, Tura JB, et al. Positivity rate, trend and associated risk factors of mother-to-child transmission of HIV among HIV-exposed infants. BMC Pediatr. 2023;23(1):283.","journal-title":"BMC Pediatr"},{"issue":"1","key":"20761_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-016-0112-0","volume":"13","author":"T Olana","year":"2016","unstructured":"Olana T, Bacha T, Worku W, Tadesse BT. Early infant diagnosis of HIV infection using DNA-PCR at a referral center: an 8 years retrospective analysis. AIDS Res Therapy. 2016;13(1):1\u20137.","journal-title":"AIDS Res Therapy"},{"key":"20761_CR26","unstructured":"Organization WH, Ethiopia HIV, country profile, WHO. ; 2023 https:\/\/cfs.hivci.org\/index.html"},{"issue":"11","key":"20761_CR27","doi-asserted-by":"publisher","first-page":"e007328","DOI":"10.1136\/bmjgh-2021-007328","volume":"6","author":"H Gesesew","year":"2021","unstructured":"Gesesew H, Berhane K, Siraj ES, Siraj D, Gebregziabher M, Gebre YG, et al. The impact of war on the health system of the Tigray region in Ethiopia: an assessment. BMJ Global Health. 2021;6(11):e007328.","journal-title":"BMJ Global Health"},{"key":"20761_CR28","doi-asserted-by":"crossref","unstructured":"Mesfin B, Mersha Demise A, Shiferaw M, Gebreegziabher F, Girmaw F. The effect of armed conflict on treatment interruption, its outcome and associated factors among chronic disease patients in North East, Amhara, Ethiopia, 2022. Patient Related Outcome Measures. 2023:243\u2009\u2013\u200951.","DOI":"10.2147\/PROM.S388426"},{"issue":"8","key":"20761_CR29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/QAD.0b013e3281532b19","volume":"21","author":"CPS Scavalli","year":"2007","unstructured":"Scavalli CPS, Mandelbrot L, Berrebi A, Batallan A, Cravello L, Pannier E, et al. Twin pregnancy as a risk factor for mother-to-child transmission of HIV-1: trends over 20 years. Aids. 2007;21(8):993\u20131002.","journal-title":"Aids"},{"key":"20761_CR30","unstructured":"UNAIDS W. AIDS Programme. Guidance on provider-initiated testing and counseling in health facilities. World Health Organization; 2007."},{"issue":"1","key":"20761_CR31","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2352-3018(22)00289-2","volume":"10","author":"GW Lyatuu","year":"2023","unstructured":"Lyatuu GW, Urrio R, Naburi H, Lyaruu P, Simba B, Siril H, et al. Vertical HIV transmission within 18 months post partum among women on lifelong antiretroviral therapy for HIV in Dar Es Salaam, Tanzania: a prospective cohort study. Lancet HIV. 2023;10(1):e33\u201341.","journal-title":"Lancet HIV"},{"key":"20761_CR32","doi-asserted-by":"crossref","unstructured":"Aguti I, Kimbugwe C, Apai P, Munyaga S, Nyeko R. HIV-free survival among breastfed infants born to HIV-positive women in northern Uganda: a facility-based retrospective study. Pan Afr Med J. 2020;37(1).","DOI":"10.11604\/pamj.2020.37.297.22928"},{"issue":"1","key":"20761_CR33","doi-asserted-by":"publisher","first-page":"21947","DOI":"10.7448\/IAS.20.1.21947","volume":"20","author":"AD Haas","year":"2017","unstructured":"Haas AD, van Oosterhout JJ, Tenthani L, Jahn A, Zwahlen M, Msukwa MT, et al. HIV transmission and retention in care among HIV-exposed children enrolled in Malawi\u2019s prevention of mother\u2010to\u2010child transmission programme. J Int AIDS Soc. 2017;20(1):21947.","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"20761_CR34","doi-asserted-by":"publisher","first-page":"e0237993","DOI":"10.1371\/journal.pone.0237993","volume":"15","author":"MG Lain","year":"2020","unstructured":"Lain MG, Chicumbe S, de Araujo AR, Karajeanes E, Couto A, Giaquinto C, et al. Correlates of loss to follow-up and missed diagnosis among HIV-exposed infants throughout the breastfeeding period in southern Mozambique. PLoS ONE. 2020;15(8):e0237993.","journal-title":"PLoS ONE"},{"issue":"4","key":"20761_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/cid\/cix820","volume":"66","author":"T-H Dinh","year":"2018","unstructured":"Dinh T-H, Mushavi A, Shiraishi RW, Tippett Barr B, Balachandra S, Shambira G, et al. Impact of timing of antiretroviral treatment and birth weight on mother-to-child human immunodeficiency virus transmission: findings from an 18-month prospective cohort of a nationally representative sample of mother\u2013infant pairs during the transition from option A to option B\u2009+\u2009in Zimbabwe. Clin Infect Dis. 2018;66(4):576\u201385.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"20761_CR36","first-page":"224","volume":"58","author":"H Moges","year":"2011","unstructured":"Moges H, Carla J, Chibwesha M, Mark J. Optimal time on HAART for prevention of MTCT of HIV. J AID. 2011;58(2):224\u20138.","journal-title":"J AID"},{"issue":"30","key":"20761_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0968-8080(07)30337-6","volume":"15","author":"N Druce","year":"2007","unstructured":"Druce N, Nolan A. Seizing the big missed opportunity: linking HIV and maternity care services in sub-saharan Africa. Reprod Health Matters. 2007;15(30):190\u2013201.","journal-title":"Reprod Health Matters"},{"issue":"2","key":"20761_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/INF.0000000000001700","volume":"37","author":"S Beste","year":"2018","unstructured":"Beste S, Essajee S, Siberry G, Hannaford A, Dara J, Sugandhi N, et al. Optimal antiretroviral prophylaxis in infants at high risk of acquiring HIV: a systematic review. Pediatr Infect Dis J. 2018;37(2):169\u201375.","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"20761_CR39","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","volume":"7","author":"A Calmy","year":"2020","unstructured":"Calmy A, Sanchez TT, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020;7(10):e677\u201387.","journal-title":"Lancet HIV"},{"issue":"9","key":"20761_CR40","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1016\/S2214-109X(20)30288-6","volume":"8","author":"AB Hogan","year":"2020","unstructured":"Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al. Potential impact of the COVID-19 pandemic on HIV, Tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Global Health. 2020;8(9):e1132\u201341.","journal-title":"Lancet Global Health"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-20761-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-20761-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-20761-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T09:07:10Z","timestamp":1733216830000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-20761-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["20761"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-20761-w","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained from the ethical review boards of the Hawassa University College of Medicine and Health Sciences institutional review board (IRB), with reference number (IRB\/076\/2022, dated December 10\/2022). The members of the ethics committee include Dr. Embiale Mengiste, Dr. Muhammed Ayalew and Dr. Freshet Assefa. Informed consent was waived based on the use of anonymized data from routine healthcare records.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"All data relevant to the study are included in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"Ethical approval was obtained from the ethical review boards of the Hawassa University College of Medicine and Health Sciences institutional review board (IRB). The members of the ethics committee include Dr. Embiale Mengiste, Dr. Freshet Asefa, Dr. Muhammed Ayalew. Informed consent was waived based on the use of anonymized data from routine healthcare records.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"not applicable Patient and public involvement: Patients or the public were not involved in the design, or conduct, or reporting. However, we will involve the public or stakeholders during dissemination of the result.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}}],"article-number":"3367"}}